Calypte to raise $2.8 million in private placement:
This article was originally published in Clinica
Executive Summary
Calypte Biomedical is to raise around $2.8 million in a private placement, through offering 3.1 million shares to institutional investors. Calypte, of Berkeley, California, recently received FDA clearance for its urine-based HIV test, consisting of an HIV-1 enzyme immunoassay antibody screening test and a Western blot confirmatory test for the results of the screening test.